ORIGINAL ARTICLE

Year : 2015 | Volume : 81 | Issue : 4 | Page : 356-362

A randomized controlled trial to compare cure and relapse rate of paucibacillary

multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among
paucibacillary leprosy patients in Agra District, India

Anil Kumar1, Anita Girdhar2, Bhuvneswar Kumar Girdhar2

1
Department of Biostatistics and Epidemiology, National JALMA Institute for Leprosy and
Other Mycobacterial Diseases (ICMR), Agra, India
2
Clinical Division, National JALMA Institute for Leprosy, Agra, India

Date of Web Publication 3-Jul-2015

Correspondence Address:
Anil Kumar
Department of Biostatistics and Epidemiology, National JALMA Institute for Leprosy and
Other Mycobacterial Diseases (ICMR), Agra
India
Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.159929

Clinical trial registration REF/2013/11/005995 dated 22/11/2013

Abstract

Objectives: To study cure rate and relapse rate of standard World Health Organization
paucibacillary multidrug therapy (PB-MDT) with monthly rifampicin, ofloxacin, and
minocycline for six months (ROM-6) among paucibacillary leprosy patients. Methods: A
total of 268 patients, detected during active search in Agra district during 2001-2004, who
had paucibacillary (PB) leprosy having 1-5 skin lesions and/or one nerve
thickening/tenderness, were allocated, using random number tables, to two treatment groups;
PB-MDT and ROM-6. On the first day of the month, dose of PB-MDT and of the ROM were
given under supervision for 6 months. After completion of drug therapy, patients were
followed every 6 months for first 5 years and later annually for next 3 years for monitoring

1
disease status, cure rates, reactions and relapses. Ci u test was used to compare relapse
rates. Results: The cure rate at 2 years was 99% in ROM-6 and 97.0% in PB-MDT group, of
those who completed treatment and the difference was statistically not significant. At 5 years,
only 88 patients in PB-MDT group and 90 patients in ROM-6 group could be followed; all
were observed to be cured. However, during the period of 5-8 years, 3 of 67 patients in PB-
MDT group and 1 of 73 in ROM-6 group were observed to have relapsed. In all, 10 relapses
were noted (3 in ROM-6 and 7 in PB-MDT group) giving a relapse rate of 1.10/100 person
years in PB-MDT and 0.435/100 person years in ROM groups (P = 0.053 ; statistically not
significant). Of the 10 relapses, 5 occurred within 5 years (3 in PB-MDT group and 2 in
ROM-6), 4 during 5-8 years (3 in PB-MDT and 1 in ROM-6), and 1 occurred in MDT group
after 8 years. Limitation: A number of patients were lost to follow up after release from
treatment and thus actual number of relapses in the study could not be assessed. Additionally,
diagnosis was purely clinical and histology could not be done for reasons related to functional
difficulties in the field. Conclusion: The study shows that PB-MDT and ROM-6 have almost
similar acceptability, cure rate and relapse rate.

Keywords: Minocycline, multidrug therapy, ofloxacin, paucibacillary leprosy, rifampicin

How to cite this article:

Kumar A, Girdhar A, Girdhar BK. A randomized controlled trial to compare cure and relapse
rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline
among paucibacillary leprosy patients in Agra District, India. Indian J Dermatol Venereol
Leprol 2015;81:356-62

How to cite this URL:

Kumar A, Girdhar A, Girdhar BK. A randomized controlled trial to compare cure and relapse
rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline
among paucibacillary leprosy patients in Agra District, India. Indian J Dermatol Venereol
Leprol [serial online] 2015 [cited 2017 Mar 2];81:356-62. Available
from: http://www.ijdvl.com.sci-hub.bz/text.asp?2015/81/4/356/159929

2
Introduction

There has been a perceptible decline in the prevalence of leprosy in the world, particularly in
the countries of South East Asia region where leprosy was earlier highly endemic. Even
though leprosy control program has changed strategies, as many as 189,018 new cases of
leprosy were registered globally in the beginning of 2013 of which two thirds were reported
in India alone. [1] Recent leprosy data gathered by the national health system in India reveal
that about half the cases registered were of multibacillary (MB) type. [2] In contrast, active
field surveys have shown that less than 20% of patients in the community are of
multibacillary type while the rest are of paucibacillary (PB) type. [3]
Among the paucibacillary cases, a significant proportion of new patients have a single
lesion. [4] A small proportion of early cases may self-heal, [5] but the risk of progressive
disease in the remaining patients if left untreated is not small. As there are no clinical and
laboratory parameters to identify this group of individuals who may worsen, it is the norm to
institute treatment in all patients to prevent the possible risk of severe disease, deformities
and reduce the spread of infection.
For the success of any mass treatment program, easy, short, effective and safe treatment that
could be given under supervision is considered suitable. The paucibacillary (PB) regimen, as
recommended by the World Health Organization (WHO), is given world over for this
subgroup of patients. It is important to note that paucibacillary multidrug therapy (PB MDT)
has been in use since 1982 and identification of alternative effective chemotherapeutic
regimen may be useful in those who may need it.
Single monthly dose therapy, consisting of rifampicin, ofloxacin, and minocycline (ROM)
was thus felt useful by WHO in 1998 to be tested in these (single skin lesion) patients as an
option against the standard 6 months PB regimen. In a multicentric trial in south India [6] and
later by other workers, [7],[8] the 6-month multidrug therapy (MDT) regimen was found useful
with cure rates of 54.7% at 18 months follow-up. However, there were concerns related to
length of unsupervised therapy with dapsone, difficulties in measuring regularity in taking
treatment and its limited beneficial effect in paucibacillary cases with 2-3 skin lesions. [9] One
limitation of this study [9] was that cases without nerve thickening were treated; however, up
to 60% of cases in the PB spectrum may show this.
Moreover, for complete information on relapses, a long-term follow up is necessary. [7],[9] The
present work was, therefore, planned to test the effectiveness of ROM-6 against WHO PB-

3
MDT, since a single dose of ROM in PB leprosy had been found to be less effective as
compared to WHO PB-MDT. [9],[10]

Methods
This was a randomized field trial and was mainly aimed at comparing cure and relapse in
paucibacillary leprosy patients treated with standard WHO PB-MDT and those treated with 6
monthly doses of ROM.

Inclusion/exclusion criteria of patients for the study

Newly detected leprosy patients diagnosed clinically as paucibacillary leprosy were
included . These included patients with 1-5 skin lesions, either erythematous or
hypopigmented, with definite impairment or loss of sensation (tested with ball point pen) and
having one thickened nerve. None of the patients had taken leprosy treatment. Children aged
below 5, adults above 70, those with asthma, and pregnant, and lactating women were
excluded.

Sample size, case detection and treatment allocation

Based on the findings of a previous study comparing ROM with MDT suggesting 53.4%
efficacy at 18 months [3] in paucibacillary leprosy with 2-3 lesions, [7] it was assumed that
cure rate was likely to improve from 53.4% to 70% at 24 months after release from treatment
(RFT). Using Type-1 error as 0.05 and power of the test as 0.80 and a likely drop out of
around 5%, it was calculated [8] that 134 patients would be required in each of the two arms
of the study. Suspected cases recruited by field workers during the active field survey of the
population were initially checked by trained and experienced paramedical workers (PMW)
with 5-15 years of experience working in leprosy, and then by an experienced medical doctor.
The authors have long experience working in leprosy (AK [15 years], AG [33 years], BKG
[35 years]). After thorough clinical examination and confirmation of diagnosis, patients were
allocated randomly to either of the two treatment groups [9] till 268 patients were recruited.
For allocation of patients to the two treatment groups, 268 three-digit random numbers from
the table were written in the patient registers in advance. Patients with even numbers were
given PB-MDT and those with odd numbers were given ROM. Blinding to treatment was not
undertaken. The recruitment of patients was started on 2 June, 2001 and completed on 3 July,
2004.

4
Skin slit smears from earlobes and the edge of the skin lesions were taken in patients who
consented to the procedure. In all, 220 (82.1%) smears were collected from 268 patients, 126
in the PB-MDT group and 94 in the ROM-6 group [Table 1].

Table 1: Clinical and treatment status of patients

Ethical permission and informed consent of patients

Permission of the Human Ethics Committee of the Institute was obtained, for treatment and
for smear examination. At the time of starting treatment, all patients were informed about the
disease, its implications, treatment, possible side effects and benefits. Once consent was
obtained, they were given treatment as per the random allocation. In case of children, consent
of their parents was taken. This study is now registered on Clinical Trial Registry of India

5
vide REF/2013/11/005995 dated 22 November, 2013.

Treatment
ROM and MDT packs supplied by WHO were used for the study in both the groups. Children
aged 5-14 years were given one pack (rifampicin 300 mg, ofloxacin 200 mg, and minocycline
50 mg) and adults (aged >14 years) were given two packs in the ROM group. In the PB-MDT
group, the child and adult MDT packs were used. Monthly ROM was given under
supervision. For PB-MDT, one daily dose of rifampicin and dapsone was given under
supervision and for the remaining days, patients were advised to take dapsone daily on their
own. Treatment was continued for 6 months.

Patient counseling
Patients were counseled at the time of taking consent for starting treatment. They were
informed about possible mild discomfort, such as intolerance of drugs resulting in loose
motions, vomiting or mild weakness, and were advised to take sugar-salt or oral rehydration
salts [ORS]) solution if diarrhea or vomiting occurred, and to contact the health worker in
case of any serious side effects. A paramedical worker or doctor was to visit the patient if
needed.

Follow-up and assessment

Patients were visited by a trained paramedical worker every month for supervised drug
administration, to check the clinical condition and monitor side effects, if any. However,
formal assessment after completion of treatment for each patient was done once in 6 months.
Lesion activity, erythema, infiltration, size, any new lesion and/or new nerve thickening or
deformity was monitored and recorded. Cure of the disease was defined as complete
resolution of the lesion or patch becoming flat, hypopigmented and with decrease in size of
the lesion and/or regaining of sensation. The reasons for default were noted among those who
did not complete the prescribed treatment.

Defining relapse
The appearance of new lesion(s) or a definite increase in size of the lesion, observed by the
patient or detected by us, or appearance of nerve thickening, were taken to indicate relapse of
disease. This definition is the same as used in the single lesion study. [9] Any sudden redness
and/or swelling of the lesion (with or without a new lesion) especially in the first 6-12 months

6
of follow up was considered a late reaction. All such patients were treated with 20 mg
prednisolone equivalent per day. If there was no obvious change in the inflammation in
lesions after 4 weeks of corticosteroid treatment, the patients were considered to have
relapsed. Relapse was defined based purely on clinical signs, after ruling out reactions.

Follow-up

The study was conducted between June 2001 and November 2010. Although the initial
objective of the study was to follow patients for 5 years, 140 patients were actually followed
up for a total period of 8 years, including an interim observation at 2 years after release from
treatment (RFT). Since the intake of patients took nearly 36 months, the longer follow up
beyond 5 years was possible in a proportion of cases in both groups. Of 134 in each group at
entry, there were 100 patients in the PB-MDT group and 103 in the ROM-6 group available
for follow up at the end of 2 years; 88 in PB-MDT and 90 in ROM-6 groups at the end of 5
years; and 67 in PB-MDT and 73 in ROM-6 groups at the end of 8 years.

Statistical methods
Pearson 2 was used to compare proportions and Mantel-Haenszel test the relapse rate by
person years. [12] Cox regression analysis was done to check the effect of confounders on
treatment outcome. Since no effect was found, these results are not presented.

Results

Characteristics of patients

[Table 2] presents details of patients in the two groups at inclusion. The age distribution of
cases suggests that patients were comparable (mean 36.4 years in the PB-MDT group vs. 40.2
years in ROM group, P = 0.059). There were more women (62.3%) in the study because they
stay at home and are more likely to be detected during active household surveys.

7
Table 2: Characteristics of patients included in the study (ROM vs. MDT)

The mean duration of disease at detection was also not significantly different (32.0 months in
ROM vs. 35.8 months in MDT), (t = 1.09, P = 0.29). As seen from [Table 2], 40.6% of
patients in the ROM arm had untreated disease of shorter duration (<12 months) as compared
with 31.3% in the PB-MDT arm.

In both groups of the study, about a third of patients had a single lesion on the skin and about
10% presented with 4-5 skin lesions. All the nerves were palpated in each patient but about
one-third of patients (33.6% in the PB-MDT group and 31.3% in the ROM group) did not
have any nerve thickening while 67.5% (66.4% in the PB-MDT group and 68.7% in the
ROM group) had1 thickened nerve [Table 1]. Skin smears could be done in 82% of the

8
patients of whom all but two were negative. Both the positive patients had low BI (1+) and
were continued on PB-MDT treatment by default as the smear results were available late, by
which time the patients had taken treatment for two months and were responding.

Effect of confounders

The Cox regression analysis was done using age, sex, duration of disease, and treatment
regimen but none of these factors was found to affect cure rates significantly (P > 0.05). Thus
it was assumed that these did not act as confounders to affect the cure rate by the respective
treatment.

Status at release from treatment

In this study, it was observed that 107 (79.9%) patients in the PB-MDT group and 115
(85.8%) patients in the ROM-6 group had completed their treatment and the rest discontinued
(defaulted) at various stages. Of the 46 cases who discontinued treatment, 35 (76.1%) did so
in the first 2 months itself, and then the number of defaulters declined as the treatment
schedule progressed [Table 1]. The reasons for default or discontinuation of treatment as
reported by patients included a feeling of weakness/intolerance following intake of drugs,
swelling of feet, vomiting/diarrhea, feeling that they were cured and discontinuation due to
pregnancy or lost to treatment. One patient felt stigmatized in taking drugs and refused to
continue treatment [Table 3].

Table 3: Reasons of default in two treatment arms of PB leprosy

At the time of completion of 6 months therapy, that is, on release from treatment (RFT), the
clinical status of the patients suggested that 69 (51.5%) in the PB-MDT group and 68

9
(50.7%) in the ROM-6 group had complete healing of their lesion(s), whereas 33 (24.6%) in
the PB-MDT group and 39 (29.1%) in the ROM-6 group had partial healing of lesions or
showed no improvement. One patient in the PB-MDT group developed type 1 reaction at
release from treatment (RFT). A total of 7 (5.2%) patients were lost to follow up in the ROM-
6 group and could not be located after the last dose was given to them, the remaining number
is accounted for by defaulters; 27 (20.1%) in PB-MDT and 19 (14.2%) in ROM-6 group.
Four (3%) patients in the PB-MDT group did not show any improvement at release from
treatment (RFT) as compared with 1 (0.8%) in the ROM-6 group [Table 1]. None of these
differences were statistically significant.
Treatment and observations
Observations at the end of 2 years: At the end of 2 years, 100 patients in the PB-MDT group
and 103 in the ROM-6 group were followed up. In the PB-MDT group, 97 (97%) were cured
for the disease, 1% still continued with active disease, two cases of reaction, and one relapse
were observed. Whereas in ROM group, of the 103 patients that were followed up, 99% were
cured of the disease, 1% still continued with active disease, no reactions but 2 relapses were
observed. This difference was statistically not significant

Observations at the end of 5 years: At the end of 5 years, only 88 patients of MDT group and
90 of ROM group could be followed up. In MDT group, all the patients were observed to be
cured of the disease. Although two cases of reaction were seen within the first 6 months in
this MDT group, no more reactions were observed during the 2-5 years period. However, 3
relapses were detected during this period. In ROM-6 group, all the 90 (100%) were cured of
the disease, no new reaction or relapse, except for the 2 relapses detected earlier, were
observed.

Observations at the end of 8 years and beyond: At the end of 8 years, 67 patients from the
MDT group and 73 in the ROM-6 group were followed up. In the MDT group, 95.5% were
observed to be cured of the disease, and 6 relapses (3 more than during the 5-8 year period)
were observed. In the ROM group, of the 73 patients, 72 (98.6%) were cured of the disease
and 3 relapsed (1 more than during the 5-8 year period).

A small group of patients (17 in the PB-MDT and 16 in ROM-6 groups) were also observed
beyond 8 years. All the patients in the ROM-6 group were observed to be cured, and there
were no further relapses or reactions. However, in the MDT group, 94.1% were cured, with

10
one new relapse.

The overall cure rates were observed to be 93.3% (97/104) in the MDT group and 97.2%
(105/108) in the ROM-6 group. Although ROM cured more patients, the difference was not
statistically significant.

The mean duration of follow up was 6.25(SD = 2.1) years; 6.12 (SD = 1.97) years in the
MDT and 6.37 (SD = 2.30) years in the ROM-6 groups respectively.

For a comparison of the overall frequency of relapses in the two groups, 3 relapses in ROM-6
group for an observation period of 688.1 patient years (PY), gives a relapse rate of
0.445/100PY and 7 relapses in the MDT group occurred in 636.4 PY with a relapse rate
1.10/100 PY. The difference in the two groups was not statistically significant (C2MH =
3.76, P = 0.053) [Table 4].

Table 4: Comparison of relapse rate in two treatment groups

Cure rates in defaulters

An attempt was made to contact the defaulters and monitor their clinical progress at the end
of the study. Among 19 defaulters in the ROM-6 group, 9 (47.4%) could be traced, 8 (88.8%)
of whom were found to have been completely cured at the time of last visit.One person
continued to have active disease, and also developed grade 2 disability. Of the 27 defaulters
in PB-MDT group, 23 (85.2%) could be traced and 19 (82.6%) were found to have been
cured but 4 (17.4%) still had active disease.

11
Discussion

In an attempt to explore alternative leprosy treatment, single dose therapy for early leprosy
had been field tested and one dose of ROM was reportedto be "almost as effective "as
standard 6 months WHO-PB regimen in treatment of single lesion PB leprosy. [6] The cure
rates at the end of the study at 18 months were 54.7% in the MDT arm and 46.9% in ROM
arm respectively, which was not significantly different. Clinical improvement at 18 months
was seen in over 99% patients in both the groups. A recent study has also clearly revealed
that efficacy of ROM therapy was as high as 93% at 2 years in curing single lesion PB
leprosy. [11] However, a systematic review to examine the role of single dose ROM has
suggested that it was less effective in curing paucibacillary leprosy than the conventional
WHO-MDT given for 6 months, and emphasized the need for trials comparing effectiveness
of multidose ROM versus standard 6 monthly WHO-MDT in paucibacillary and
multibacillary leprosy. [13]

In the present study, observations at the end of 5 years suggested a 100% cure in the PB-
MDT group with 3 relapses, in comparison with a 100% cure and 2 relapses in the ROM-6
group. However, at the end of 8 years, relapses in the PB-MDT group doubled to 6 with a
cure rate of 95.5% among those followed up, in comparison with 3 relapses in the ROM-6
group and a 98.6% cure rate.

In the studies mentioned earlier, disease regression had been the main outcome
criteria. [6],[7],[8] However, of late, reports of relapses in patients treated with a single dose of
ROM have been published. [14],[15],[16] In a report by WHO, a relapse rate of 3/1000 person
years at risks (PYAR) has been mentioned. [17] In Bangladesh, a relapse rate of 5.09/1000
person years at risks was observed in patients treated with ROM and followed up for 4.5
years. [16]

In view of the high relapse rate even in patients with a single skin lesion, we considered that
repeating monthly ROM for 6 months could be a better option, especially considering the fact
that our study included all PB cases with upto 5 lesions with/without 1 main nerve. This
enabled us to compare a totally supervised regimen with a treatment schedule that is partly
self- administered. The drugs included in the once-monthly regimen have all been shown to
have potent bactericidal action on Mycobacterium leprae both in footpad of mice and in

12
human patients. The patients in this study have been observed for over 5 years to compare the
long-term outcome of the two treatment regimens.

In the present study, a few cases of Type 1 reactions were observed. It could be possible that
some reactions might have been treated by other practitioners for reaction and not reported
due to follow up being recorded only at 6 month intervals.

The present study has shown that the cure rates in patients who completed treatment in the
two groups continued to improve at 6, 12 and 18 months after therapy reaching an overall
cure rate of 93.3% in the PB-MDT and 97.2% in ROM-6 groups [Table 5]. The number of
patients showing clinical response in the ROM-6 group indicates the efficacy of 6 monthly
doses of ROM in paucibacillary patients. The cure rate with ROM-6 was similar to that of
PB-MDT. The relapse rates, although more in number in the PB-MDT group than in the
ROM-6 group, were not statistically significantly different. Thus, the study results clearly
demonstrate that ROM-6 is an acceptable supervised therapy for PB leprosy which could be
an effective alternative to PB-MDT.
Table 5: Events rates in those completed treatment by treatment arms of PB leprosy

The study has limitations. A good number of patients were lost to follow up after release
from treatment and thus actual number of relapses in the study could not be assessed.
Additionally, diagnosis was purely clinical and histology could not be done for reasons
related to functional difficulties in the field.

13
Acknowledgment

The authors thank the Director of the institute for help provided in carrying out this study and
also to project staff (PMWs - Sanjiv Tiwari, Raghvendra Singh, Rabaendra Kumar) and all
the patients who gave their time and cooperation for the study. The authors would also like to
thank the anonymous reviewers for IJDVL who helped to improve the write up.

14
References

1. WHO. Global leprosy-an update on 2012 situation. Wkly Epidemiol Rec

2013;88:365-80.
2. NLEP, Ministry of Health and Family welfare, Govt of India, 2012. Available from:
http://www.nlep.gov.in.secure.sci-hub.cc [Last accessed on 2013 Apr 12].
3. Kumar A, Girdhar A, Chakma JK, Girdhar BK. Detection of previuosly undetected
leprosy cases in Firozabad District (U.P.), India during 2006-09: A Short
communication. Lepr Rev 2013;84:124-7.
4. Progress towards elimination of leprosy as public health problem. Wkly Epidemiol
Rec 1996;71:149-56.
5. Ekambram V, Sithambram M. Self healing in non-lepromatous leprosy in the area of
ELEP Leprosy Control Project, Dharampuri (Tamilnadu). Lepr India 1977;49:387-92
6. Efficacy of single dose multidrug therapy for the treatment of single lesion
paucibacillary leprosy.Single Lesion Multicentric Trial Group. Indian J Lepr
1997;69:121-9.
7. Revenkar CR, Pai VV, Antony Samy MS, Ganapati R. Single-dose treatment for PB
leprosy; Field implications. Int J Lepr Other Mycobact Dis 1999;67:312-3.
8. Ganapati R, Revenkar CR, Pai VV, Kingslley S. Single-dose treatment for PB
leprosy; feasibility of long term follow up. Int J Lepr Other Mycobact Dis
1999;67:308-9.
9. 2-3 lesion Multicentric Trial Group. A comparative trial of single dose chemotherapy
in paucibacillary leprosy patients with 2 to 3 skin lesions. Indian J Lepr 2001;73:131-
43.
10. Setia MS, Shinde SS, Jerajani HR, Boivin JF. Is there a role for rifampicin, Oflozacin
and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and
meta analysis. Trop Med Int Health 2011;16:1541-51.
11. Dupont WD, Plummer WD.PS Power and Sample Size Calculations.Version 3.0,
January 2009.
12. Fleiss JL. Statistical Methods for rates and proportions. 2 nd ed, New York: John
Wiley and Sons; 1981.
13. Girdhar A, Kumar A, Girdhar BK. A randomized controlled trial assessing the effect
of adding clariithromycin to Rifampicin, Ofloxacin and Minicycline in the treatment

15
 of Single lesion paucibacillary leprosy in Agra District, India. Lepr Rev 2011;82:46-
54.
14. Shetty VP, Wakade AV, Antia NH, Pai VV, Revenker CR, Ganapati R, et al. Clinical,
histopathological and bacteriological investigations in two cases of relapse following
ROM treatment. Lepr Rev 2001;72:83-7.
15. Shukla P, Miranda MS, Prabhudesai R, Rege VL. Single dose ROM therapy in Goa.
Indian J Lepr 2002;74:169-72.
16. Alam K, Butlin CR, Pahan D, Kumar S, Chowdhury. Long term follow-up of ROM
treated cases. Lepr Rev 2007;78:160.
17. World Health Organization. WHO Tech Advisory Group on Leprosy Control, Report,
(Section 6. Clinical trials for treatment for paucibacillary leprosy with single dose of
rifampicin, ofloxacin and minocycline: final Report).1994.

16